GlaxoSmithKline plc (LON:GSK) insider Emma Walmsley bought 8 shares of the company’s stock in a transaction dated Thursday, August 9th. The shares were acquired at an average cost of GBX 1,593 ($20.55) per share, with a total value of £127.44 ($164.40).
LON:GSK traded down GBX 13 ($0.17) during mid-day trading on Tuesday, hitting GBX 1,571.60 ($20.27). The stock had a trading volume of 6,311,427 shares, compared to its average volume of 9,120,000. GlaxoSmithKline plc has a twelve month low of GBX 1,235.20 ($15.93) and a twelve month high of GBX 1,724.50 ($22.25).
The company also recently announced a dividend, which will be paid on Thursday, October 11th. Investors of record on Thursday, August 9th will be issued a GBX 19 ($0.25) dividend. The ex-dividend date of this dividend is Thursday, August 9th. This represents a yield of 1.23%.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Recommended Story: Closed-End Mutual Funds (CEFs)
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.